Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Liwen Xiong"'
Autor:
Bo Zhang, Hongyu Liu, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Tianqing Chu, Huimin Wang, Liwen Xiong, Wei Zhang, Xueyan Zhang, Bo Yan, Jiajun Teng, Weimin Wang, Hao Bai, Rong Qiao, Lei Cheng, Yanbin Kuang, Ruiying Zhao, Hua Zhong, Baohui Han
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) represents a major unmet medical need in non-small cell lung cancer (NSCLC) patients. Vascular endothelial growth factor (VEGF) inhibition may reverse a suppressive microenvironmen
Externí odkaz:
https://doaj.org/article/fd0c3fa6cd7f420a97190e5951f015d2
Autor:
Bo Zhang, Hua Zhong, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Weimin Wang, Tianqing Chu, Liwen Xiong, Wei Zhang, Huimin Wang, Xueyan Zhang, Baohui Han
Publikováno v:
The Clinical Respiratory Journal, Vol 17, Iss 12, Pp 1361-1367 (2023)
Abstract Introduction Durvalumab is a check‐point inhibitor against programmed death ligand‐1 (PD‐L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical
Externí odkaz:
https://doaj.org/article/a5f8528abb824329a4d37c54d296c13e
Publikováno v:
Heliyon, Vol 10, Iss 6, Pp e27633- (2024)
Introduction: The genetic heterogeneity of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations may affect clinical responses and outcomes to EGFR tyrosine kinase inhibitors (EGFR-TKIs). This study aims to investi
Externí odkaz:
https://doaj.org/article/fc86fe16e9d949a39a56bd7a7755334d
Autor:
Lanzhi Li, Xingfei Zheng, Jiabo Wang, Xueli Zhang, Xiaogang He, Liwen Xiong, Shufeng Song, Jing Su, Ying Diao, Zheming Yuan, Zhiwu Zhang, Zhongli Hu
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Genetic improvement of grain quality is more challenging in hybrid rice than in inbred rice due to additional nonadditive effects such as dominance. Here, we describe a pipeline developed for joint analysis of phenotypes, effects, and genera
Externí odkaz:
https://doaj.org/article/da5e5c4584fe4eefb997a8f393155916
Autor:
Lei Cheng, Yanan Wang, Lixin Qiu, Yuanyuan Chang, Haijiao Lu, Chenchen Liu, Bo Zhang, Yan Zhou, Hao Bai, Liwen Xiong, Hua Zhong, Wei Nie, Baohui Han
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-14 (2022)
Abstract Background mTOR pathway is known to promote cancer malignancy and influence cancer immunity but is unknown for its role in immune checkpoint inhibitors (ICI) therapy. Methods Using Memorial Sloan-Kettering Cancer Center dataset (MSKCC), we e
Externí odkaz:
https://doaj.org/article/b788aca811734180b111227a59a56f33
Autor:
Bo Zhang, Chunlei Shi, Zhiqiang Gao, Hua Zhong, Liwen Xiong, Aiqin Gu, Weimin Wang, Tianqing Chu, Wei Zhang, Huimin Wang, Xueyan Zhang, Runbo Zhong, Baohui Han
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Dacomitinib is a second-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). ARCHER-1050 showed that this agent can improve progression-free survival and overall survival in advanced non-
Externí odkaz:
https://doaj.org/article/c59db3c5cc22409ba29a6027dbe674da
Autor:
Xiong Yuan, Zirong Li, Liwen Xiong, Sufeng Song, Xingfei Zheng, Zhonghai Tang, Zheming Yuan, Lanzhi Li
Publikováno v:
BMC Bioinformatics, Vol 23, Iss 1, Pp 1-16 (2022)
Abstract Background Plant variety identification is the one most important of agricultural systems. Development of DNA marker profiles of released varieties to compare with candidate variety or future variety is required. However, strictly speaking,
Externí odkaz:
https://doaj.org/article/46123571ef1341b6bf8741e0116363c5
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4697-4709 (2021)
Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) has been considered as an effective treatment in epidermal growth factor receptor‐mutant (EGFR‐mutant) advanced non‐small cell lung cancer (NSCLC). Ho
Externí odkaz:
https://doaj.org/article/5c3e068d5b63440ea56537f44a299edc
Autor:
Liwen Xiong, Yuqing Lou, Hao Bai, Rong Li, Jinjing Xia, Wentao Fang, Jie Zhang, Han Han-Zhang, Analyn Lizaso, Bing Li, Aiqin Gu, Baohui Han
Publikováno v:
Journal of International Medical Research, Vol 48 (2020)
Background The optimal neoadjuvant regimen for locally advanced resectable non-small cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly improved survival in patients with EGFR -mutant advanced NSCLC. However, their eff
Externí odkaz:
https://doaj.org/article/bd63fc2390494c709f9c1c3375abf0d7
Autor:
Jun Lu, Hua Zhong, Jun Wu, Tianqing Chu, Lele Zhang, Hua Li, Qiming Wang, Rong Li, Yizhuo Zhao, Aiqin Gu, Huimin Wang, Chunlei Shi, Liwen Xiong, Xueyan Zhang, Wei Zhang, Yuqing Lou, Bo Yan, Yu Dong, Yanwei Zhang, Baolan Li, Li Zhang, Xiaodong Zhao, Kai Li, Baohui Han
Publikováno v:
Advanced Science, Vol 6, Iss 19, Pp n/a-n/a (2019)
Abstract Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non‐small cell lung cancer (NSCLC) patients is still elusive. Here, tumor‐specific target capture is used to profile the circulating DNA of ALTER
Externí odkaz:
https://doaj.org/article/41d5c2e34b434da9a47c2c87053dd16d